Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Annovis Bio (ANVS), AbbVie (ABBV) and Glaukos (GKOS)...

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Envista Holdings (NVST) and Alumis Inc. (ALMS). En...

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)

An announcement from Novartis ( ($NVS) ) is now available. On September 1, 2026, Novartis reported positive topline Phase III results for remibruti...

Novartis Reports Positive Phase III Results for Oral BTK Inhibitor Remibrutinib in Relapsing Multiple Sclerosis

Dividend ETFs remain popular among investors looking for steady income and long-term stability, especially in uncertain markets. Using TipRanks Van...

Vanguard Dividend ETFs Comparison: VYMI vs. VIG vs. VYM for Income Investors

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG today and set a price target of CHF140.00. Papadakis covers the Hea...

Novartis AG (NOVN) Receives a Buy from Deutsche Bank

Some low‑priced stocks are drawing attention from Wall Street thanks to their growth plans and strong sector trends. These names trade under $10 bu...

3 Stocks Under $10 With Over 100% Upside, According to Analysts

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) ...

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

Annovis Bio Inc ($ANVS) announced an update on their ongoing clinical study. Annovis Bio Inc. has launched a new study focused on long term safety ...

Annovis Bio’s New Long-Term Safety Study Puts Buntanetap Back in the Alzheimer’s Spotlight

Envista Holdings ( ($NVST) ) has shared an update. On August 17, 2026, Envista Holdings’ board appointed President and Chief Executive Officer Paul...

Envista Holdings Elevates CEO Paul Keel to Board Chair

Dividend investing is a simple way to generate regular income. Vanguard ETFs offer a low-cost way to gain diversified income exposure with lower ri...

3 Vanguard Dividend ETFs to Boost Passive Income

Envista Holdings (($NVST)) has held its Q2 earnings call. Read on for the main highlights of the call. Envista Holdings’ latest earnings call struc...

Envista Holdings Lifts Outlook After Strong Quarter

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Envista Holdings today and set a price target of $31.00. According to TipRanks, B...

Stifel Nicolaus Sticks to Their Buy Rating for Envista Holdings (NVST)

In a report released yesterday, Vik Chopra from BMO Capital maintained a Hold rating on Envista Holdings, with a price target of $29.00. The compan...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVS	$160.33	-1.69%	200.30K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVS	$160.33	-1.7%	200.30K
3
4
5
6

NVS

Get Novartis AG Data in Excel

Get Novartis AG Data in Excel